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Abstract: Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein
virus (EBV). Clonal viral genomes can be found in the HL tumor cells, the Hodgkin Reed
Sternberg cells (HRS). The latent infection results in expression of the viral oncogenes LMP1 
and LMP2A which contribute to generate the particular phenotype of the HRS cells. EBV 
does  not  only  undergo  epigenetic  changes  of  its  genome  during  latency,  but  als
epigenetic changes in the host genome. The presence of EBV may alter the composition and 
activity of the immune cells surrounding the HRS cells. EBV favours a  Th1 reaction, but this 
attempt at a cell mediated immune response appears to be ineffe
HL is associated with several clinicopathological characteristics: It is more frequent in cases 
with  mixed  cellular  histology,  in  males,  in  children  and  older  adults,  and  in  developing 
countries, while the young-adult onset HL
is typically EBV-negative. Countries in the Mediterranean area often show  an intermediate 
epidemiological  pattern.  Recent  studies  suggest  a  genetic  predisposition  to  develop  EBV
associated  HL.  Circulating  EBV
therapy, and eventually, EBV will become a target for therapeutic intervention also in HL.
Introduction:  Since  its  first  description  by  Sir 
Thomas Hodgkin in 1832, the nature and cellular 
origin  of  Hodgkin’s  disease  has  been  an  enigma. 
There was a long-lasting controversy as to whether 
Hodgkin’s disease was a malignant, inflammatory 
or  infectious  disease.  Hodgkin’s
characterized  by  a  rare  population  of  Hodgkin 
Reed-Sternberg (HRS) cells which are surrounded 
by a massive inflammatory infiltrate. The paucity of 
the  HRS  cells  hampered  the
characterization
1. 
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Up to 40% of Hodgkin lymphoma (HL) cases are associated with the Epstein
virus (EBV). Clonal viral genomes can be found in the HL tumor cells, the Hodgkin Reed
ernberg cells (HRS). The latent infection results in expression of the viral oncogenes LMP1 
and LMP2A which contribute to generate the particular phenotype of the HRS cells. EBV 
does  not  only  undergo  epigenetic  changes  of  its  genome  during  latency,  but  als
epigenetic changes in the host genome. The presence of EBV may alter the composition and 
activity of the immune cells surrounding the HRS cells. EBV favours a  Th1 reaction, but this 
attempt at a cell mediated immune response appears to be ineffective. The presence of EBV in 
HL is associated with several clinicopathological characteristics: It is more frequent in cases 
with  mixed  cellular  histology,  in  males,  in  children  and  older  adults,  and  in  developing 
adult onset HL of nodular sclerosis type in industrialized countries 
negative. Countries in the Mediterranean area often show  an intermediate 
epidemiological  pattern.  Recent  studies  suggest  a  genetic  predisposition  to  develop  EBV
ting  EBV-DNA  may  serve  as  a  biomarker  to  monitor  response  to 
therapy, and eventually, EBV will become a target for therapeutic intervention also in HL.
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ally,  amplification  of  
immunoglobulin  genes  by  the  polymerase  chain 
reaction from isolated HRS cells helped to clarify 
the  nature  of  the  HRS  cells
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rearrangements of Ig VH genes carrying a high load 
of somatic mutations indicated an origin of the HRS 
germinal  center  B  lymphocytes
3. 
Recently, a small clonotypic B cell in the peripheral 
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Figure 1. The role of EBV in the generation of the peculiar phenotype of HRS cells. EBV preferentially infects naïve B cells and 
adapt its gene expression during B cell differentiation. HRS cells  originate from preapoptotic GC B cells. Expression of latency II 
genes in HRS cells deliver survival,  proliferation and de-differentiation signals by activating various pathways.  
consensus that the HRS cells in Hodgkin’s disease 
are  neoplastic,  and  now,  the  term  Hodgkin 
lymphoma  (HL)  instead  of  Hodgkin’s  disease  is 
recommended
5. 
An infectious aetiology has long been suspected 
in HL, and so far,  Epstein-Barr virus (EBV) is the 
only candidate for the infectious agent causing HL. 
There are several lines of evidence linking  EBV to 
the aetiology of some HL: the biological plausibility 
of  EBV-mediated  B  cell  transformation    and  
presence of clonal EBV genomes within HL tumor 
cells, which implies that infection occurred before 
malignant  transformation, epidemiologic
associations  with  infectious  mononucleosis  (IM), 
representing  symptomatic  primary  EBV  infection,
distinctive  EBV  antibody  titer  profiles  and  viral 
loads  both  pre- and  post-HL  diagnosis, and 
differing demographic, clinical, and epidemiologic 
characteristics  of  EBV+ and  EBV- HL.  Together 
this evidence  strongly suggests that these virally 
defined variants of HL are distinct entities and that 
their pathogenesis should be considered separately. 
However, only a varying proportion of HL cases are 
EBV-associated. Despite  extensive  research,  no 
other infectious agent has been so far identified
6-8.
The  large  majority  of  Hodgkin  lymphoma 
arising  in  the  setting  of  HIV  infection  are 
pathogenetically linked to EBV, with rates of EBV 
positivity ranging from 80 to 100%
9. The distinctive 
features  HIV-related  HL will  not  be  discussed in 
this review, as it is the topic of another review in 
this issue of the journal.
This review will discuss the role of EBV in the 
pathogenesis  of  HL,  the  impact  of  EBV  on 
immunological  and  clinical  characteristics,  the 
epidemiological evidences for a role of EBV in HL, 
and potential clinical applications. There have been 
excellent reviews on this topic, and therefore, we 
will focus on data from more recent publications
10-
16.
The role of EBV in transforming B cells to HRS 
cells: EBV  or  human  herpes  virus  4    is  closely 
associated with the GC B cell malignancies Burkitt 
lymphoma,  post  transplantation  lymphomas  and 
HL. HL is one of the most frequent lymphomas in 
the western world and can be divided into Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Table 1.
Expression of EBV latent genes
Latency
pattern EBNA-1 EBNA-2 EBNA-3 LMP-1 LMP-2 EBER Disease
Type  I + - - - - + Burkitt’s lymphoma
Type II + - - + + +
Nasopharyngeal carcinoma 
Hodgkin lymphoma, peripheral T 
cell llymphoma
Type III + + + + + +
Post-transplant lymphoprolifertive 
diesases
Infectious mononucleosis
Other + - - - + + Healthy carrier
lymphocyte  predominant  (LP-HL)  and  classical 
(cHL) including mixed cellularity, nodular sclerosis 
and lymphocyte-rich subtypes
17. Most cases of cHL 
and LP-HL carry clonal somatically mutated Ig V-
gene  rearrangement.  Characteristically  HRS  cells 
make only 1% of the tumor mass and show a strong 
NF-B  overexpression
18-2.  HRS  cells  of  HL  have 
lost the expression of typical B cell lineage genes 
and instead show a strong expression of signaling 
molecules  and  transcription  factors  of  other  cell 
types
22,23. About 40% of HL cases are infected with 
EBV. Clonal viral genomes can be found in all of 
the  tumor cells  and  the  virus  remains  in  the 
malignant  cells  during  the  whole  course  of 
disease
24,25.
EBV  preferentially  infects  human  B  cells,  in 
which it  mainly  persists as a  harmless  passenger. 
Over 90% of people worldwide are latently infected 
with the virus
14. In early childhood infection with 
EBV usually remains asymptomatic and leads to a 
lifelong persistency of the virus within the B cell 
compartment  with  1-10  of  10
6 B cells  being 
latently-infected
26-28. However, delayed infection in 
puberty  or  early  adulthood  can  cause  the  self-
limiting  disease  “infectious  mononucleosis 
(IM)”
29,30.  In  addition,  EBV  was  originally 
identified  in  a  Burkitt  lymphoma  biopsy  and 
therefore, was described as the first human tumor 
virus
31. Tumorigenic properties are demonstrated by 
the transformation of normal B cells into immortal 
lymphoblastoid  cell  lines  (LCLs)  after  in  vitro 
infection with EBV
32. EBV can also infect epithelial 
cells, which likely plays a role in virus propagation 
and release into the saliva
33,34.
After infection of B cells the 172 kbp viral DNA 
genome circularizes to an episome in the  nucleus 
and is subsequently amplified to 10-100 copies per 
cell
35,36.  (Figure  1).  EBV  can  express  different 
latency  programs  and  thereby  shows  a  very  high 
adaptation to the B cell physiology (Table 1). The 
first latency program to be expressed after B cell 
infection is latency III
37. Here the dependency of the 
viral  latency  III  promotor  for  the  B  cell  specific 
transcription  factor  PAX5  guarantees  B cell 
specificity  of  the  virus
38. In latency  III the  latent 
membrane  proteins  LMP1,  LMP2A  and  LMP2B, 
the nuclear proteins EBNA1, -2, -3A, -3B, -3C and 
EBNA-LP  as  well  as  two  non-polyadenylated 
RNAs, EBER1 and EBER2 and the BART RNAs 
are  expressed.  In  latency  II  only  LMP1,  LMP2A 
and  -2B,  EBNA1 and  the  EBER  and  BART 
transcripts  are  expressed
14.  Latency  I  is 
characterized  by  the  expression  of  EBER  and 
BART transcripts as well as of EBNA1 as the only 
latent  EBV protein. Latency I is  mainly found in 
Burkitt lymphoma
14.  In latency  0  only  the  EBER 
and BART transcripts and sometimes LMP2A are 
expressed
14,39-42.  It  is  speculated  that  EBV 
preferentially infects naïve B cells that get activated 
and  pass  through  a  normal  germinal  center  (GC) 
reaction. During this differentiation process latency 
programs  change  from  latency  III  to  eventually 
latency  0  in  the  long-living  memory  B  cell 
population
43. Thereby, EBV can persist in memory 
B  cells  unrecognizable  by  cytotoxic  T  cells
41. 
However, this scenario of EBV persistency remains 
controversely discussed. In IM tonsils EBV infected 
B  cell  clones  do  not  participate  in  the  GC Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
reaction
44,45.  In  addition,  histological  stainings  of 
GC in EBV persistency only rarely showed EBV +
B cells within GC
46,47.
It  is  believed  that  the  tumor  cells  in  cHL 
originate  from  preapoptotic  GC  B  cells.  This  is 
supported by the finding that in 25% of cHL cases 
the  HRS  cells  carry  B  cell  receptor  (BCR)-
destructive  mutations  in  originally  functional  V-
gene  rearrangements
3.  Normally  GC  B  cells  that 
acquire  BCR-destructive  mutations  or  mutations 
that decrease the affinity towards the antigen during 
affinity  maturation  in  the  GC  die  quickly  by 
apoptosis
48,49.  However,  in  cHL  BCR-deficient 
tumor cell precursor GC B cells survive due to a 
transformation  event.  This  transformation  event 
likely is the infection with EBV, since it was shown 
by in vitro infection of GC B cells that EBV can 
rescue  BCR-deficient  GC  B  cells  from  apoptosis 
and  transform  them  into  long-lived  cell  lines
50-52. 
This rescue is thought to be due to the expression of 
the  BCR-mimic  LMP2A that is also expressed in 
EBV+  HRS  cells
53.  In  addition,  Mancao  and 
Hammerschmidt showed that in long-term cultures 
LMP2A replaces the BCR-signal  and BCR+ cells 
even  become  dependent  on  the  expression  of 
LMP2A
54. The rescue of BCR-deficient GC B cells 
by  EBV  is  further  supported  by  the  fact  that  the 
BCR-deficient HL cases are all EBV+, whereas in 
total  only  40%  of  HL shows  an  association  with 
EBV
17.  The  role  of  EBV  LMP2A  in  HL 
pathogenesis  likely  confers  to  early 
lymphomagenesis, where the signaling molecules of 
LMP2A and BCR were still expressed. 
The transcription factor NF-B seems to play a 
major role in the rescue of HRS precursor cells. NF-
B  activates  the  expression  of  the  anti-apoptotic 
DISC-inhibitor c-FLIP and induces the expression
of pro-inflammatory cytokines
55-57. In EBV+ HL the 
virus displays a latency II gene expression pattern, 
including  the  expression  of  LMP1,  LMP2A  and 
EBNA1.  LMP1  mimics  a  constitutively  active 
CD40 receptor, thereby acting as a strong activator 
of  NF-B,  and  is  presumably  responsible  for  the 
constitutive  NF-B expression in EBV+ HL
cases
23,58-60. Until recently the cause of the NF-B 
overexpression in the EBV- HL cases was largely 
unknown.  Genetic  aberrations  of  the  NF-B 
inhibitors IB and IB and amplifications of c-
rel could be found in only some cases
61-65. Recently 
Schmitz and colleagues showed that the constitutive 
activity of NF-B in about 50% of primary EBV-
cHL is likely caused by inactivating mutations in 
both  of  the  A20 tumor  suppressor  gene  alleles
66. 
A20 inactivating mutations exclusively in EBV- HL 
cases seem to replace the transforming and NF-B-
activating  role  of  LMP1  in  EBV+  HL  cases  and 
demonstrate  the  essential  role  of  EBV  in  the 
pathogenesis of EBV+ HL.
Recent papers addressed the effect of EBV gene 
products  on  the  expression  of  B  cell-specific 
differentiation antigens. Vockerodt and colleagues 
used  a  non-viral  vector-based  method  to  express 
LMP1  in  primary  human  GC  B  cells
67.  Gene 
expression profiling revealed that LMP1 induced in 
GC B cells transcriptional changes characteristic of 
HL cell lines. Strikingly, LMP1 down-regulated the 
expression of B-cell-specific genes including B-cell 
receptor  components  such  as  CD79A,  CD79B, 
CD19,  CD20,  CD22,  and  BLNK.  LMP1  also 
induced the expression of ID2, a negative regulator 
of  B-cell  differentiation.  As  well,  expression  of 
LMP2A as a transgene resulted in   global down-
regulation  of  gene  transcription  necessary for 
proper B-cell development
68. 
A tissue microarray analysis on 288 HL biopsies 
showed a specific gene expression profile for EBV+ 
cases.  The  presence  of  EBV  correlated  strongly 
with  the  expression  of  STAT1  and  STAT3,  but 
inversely with the expression of cyclin E, CDK6, 
p27, p53, HDM2, and BCL-XL
69. 
EBV and epigenetic changes: EBV may modulate 
cellular  gene  expression  also  by  induction  of 
epigenetic  changes  which result  in  inducing  gene 
silencing
70,71. LMP1 is able to induce the expression 
of the DNA methyltransferases DNMT1, 3A, and
3B  in  latently  infected  cells
72.  In  nasopharyngeal 
carcinoma  (NPC)  cells,  LMP1  activates  DNMT1 
through the activation of c-Jun NH2-terminal kinase 
(JNK)-activator  protein-1  (AP-1)  signaling
73.  Seo 
and colleagues also suggested a role for the Rb-E2F 
pathway  in  LMP1-induced  DNMT1  activation  in 
NPC cells
74. 
Modulation of the host methylation system may 
have  implications  for  the  pathogenesis  of  EBV-
associated  tumors.  For  gastric  carcinomas,  it  has 
been  reported  that  the  methylation  frequency  of 
tumor  suppressor  genes is  much  higher  in  EBV+ 
than EBV- cases, indicating a possibility that EBV 
induces  the  hypermethylation  of  cellular  genes 
critical  to  tumor  pathogenesis.  Interestingly, 
activation of DNMT1 appears not to be limited to 
EBV-induced  tumorigenesis,  but  it  was  recently 
suggested to  play an essential role in aberrant de 
novo  methylation  in  various  tumors  which  are 
associated  with  viral  infection,  such  as  tumors 
infected with the human papillomavirus-16 or the 
hepatitis B virus
75,76. Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
The  EBV  genome  undergoes  changes  in  CpG
methylation which appear to play an important role 
in  regulating viral latency and limiting viral gene 
expression  in  normal  lymphocytes  and  in 
tumors
77,78.  The  EBV  genome  is  highly 
unmethylated  in  infectious  virions  and  in  latency 
III. During B cell transformation, the viral genome 
is  increasingly  methylated  upon  cell  propagation, 
which  may  reflect  the  in  vivo  situation  of  a 
transition  from  an  EBV-infected  lymphoblastoid 
proliferating  B  cell  to  latently  infected  B-cells 
(latency  II, I or 0) in normal lymphoid tissues in 
healthy  individuals
79.  In  normal  lymphocytes  and 
tumors from immune competent patients, some of 
the  EBV  latent  promoters  need  to  be 
downregulated,  in  order  to  silence  or  limit  viral 
immunodominant  gene expression and thus evade 
the  host  immune  surveillance
78.  A  complex 
transcriptional  regulation  of  these  EBV  genes 
allows  the  virus  to  persist  in  the  host  with  or 
without a potent immune response. Methylation of 
EBV genes is achieved by taking advantage of the 
host cell DNA methylation system. Treatment with 
demethylating  agents  such  as  the  DNA 
methyltransferase  inhibitor  5-azacytidine  can 
reactivate  the  transcription  of  methylated  EBV 
genes  along  with  the  demethylation  of  their 
promoters
80. This may have implications for EBV-
directed therapeutic approaches.
Interaction  of  EBV + - HRS  cells  with  the 
microenvironment and the immune system: The 
clinical and pathologic features of cHL reflect an 
abnormal immune response that is thought to be due 
to the elaboration of a variety of cytokines by the 
malignant Reed-Sternberg (RS) cells or surrounding 
tissues
81.  The  majority  of  cHL  cases  are 
characterized by expression of tumor necrosis factor 
receptor (TNFR) family members and their ligands, 
as  well  as  an  unbalanced  production  of  Th2 
cytokines  and  chemokines.  The  production  of 
cytokines  play  a  pivotal  role  in  the 
immunopathogenesis of HL, as these factors can act 
both  as  autocrine  growth  factors  or  as  factors 
initiating  and  sustaining  the  reactive  infiltrate.  In 
addition,  cytokines  produced  by  the  surrounding 
cells  of  the  microenvironment  may  contribute  to 
stimulate HRS cell survival and proliferation.
The presence of EBV may alter the expression 
of cytokines and chemokines. In fact, EBV favors a 
Th1  reaction  in  the  HL  microenvironment.  The 
expression of IL-12, which is responsible for Th1-
cell differentiation, and chemokines that support a 
Th1 response (IP-10, Mig, MIP-1) are expressed 
at higher levels in EBV+ HL cases than in EBV-
cases
82.  Accordingly,  CD8+  T  cells  are  more 
numerous in the reactive infiltrate of EBV+ cases. 
However, this attempt at a cell mediated immune 
response in EBV+ cases appears to be ineffective, 
because there is a local suppression of cytotoxic T 
cells  specifically  targeting  EBV  antigens.  This 
suppression may be due to the presence of IL-10, a 
potent  anti-inflammatory  cytokine  frequently 
produced by RS cells in EBV+ cHL cases. LMP1 
can  induce  cellular  IL-10  expression  in  EBV+ 
cells
83.  Herling  et  al,  studying  577  HL  patients, 
reported higher IL-10 levels in EBV+ cases
84. 
IL-6 is another cytokine whose expression has 
been  reported  to  be  increased  in  EBV+ tumors
85. 
However,  associations  between  cytokine  levels  in 
peripheral  blood  and  EBV  tumor  status  have  not 
always produced unequivocal correlations
86,87.  
A  recent  study  demonstrated  an  increased 
expression  of  CCL20,  a  chemokine  capable  of 
attracting  Treg  cells,  in  the  microenvironment  of 
EBV+ versus EBV- RS cells
88.  Another cytokine 
whose expression has been reported to be increased 
in  EBV+  tumors  is  autotoxin
89.  Autotaxin  is  an 
autocrine motility factor with lysophospholipase-D 
activity  generating  lysophosphatidic  acid  (LPA) 
which enhances growth and survival of HL cells, 
whereas  specific  down-regulation  of  autotaxin 
decreased LPA levels and reduced cell growth and 
viability. 
The  development  of  molecular  profiling 
techniques  made  it  possible  to  establish  more 
comprehensive gene expression patterns of EBV+ 
HL  tissues.  EBV+  tumors  are  characterized  by  a  
robust  gene  signature  involving  innate  immunity
and  antiviral  responses
90.  The  molecular  profiling 
confirms  that  EBV  favors  a  Th1  reaction  with 
simultaneous  overexpression  of  IFN,  CXCL9, 
CXCL10,  and  CXCL11/ITAC  and  observes  an 
antiviral  response  with  overexpression  of  genes 
such as IVNS1ABP (NS1BP), PLSCR1, and OAS. 
Histopathological differences between EBV+ and 
EBV- HL: Weiss et al were the first to demonstrate 
the presence of EBV DNA in HL tissue specimens 
using the cloned BamHI-W fragment of EBV, as a 
probe  for  in-situ  hybridization  (ISH)
25.  The 
subsequent development of ISH targeting the highly 
abundant  EBERs  provided  a  reliable  and  simple 
method  for  the  detection  of  EBV  in  archival  HL 
specimens
91.  HL can  be  classified  into  two
clinicopathological entities: the nodular lymphocyte
predominant type (NLPHL) which represents 5% of 
cases and are virtually never associated with EBV,Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 2. Age-specific incidence of HL according to EBV status and countries’ development based on the model by Jarrett (93) and 
data from Parkin DM et al; Cancer incidence in five continents; VIII, updated. IARC cancer Base No.7. Lyon, France: International 
Agency for Research on Cancer, 2005
and  the  classical  HL, which  can  be  further 
subdivided in four morphological subtypes: nodular 
sclerosis (NSHL) which accounts for the majority 
of  cases,  mixed  cellularity  (MCHL),  lymphocyte-
rich (LRHL) and lymphocyte-depleted (LDHL). As 
LHRL and LDHL each comprise less than 5 % of 
cases of HL, most of the data on EBV are derived 
from  studies  on  NSHL  and  MCHL.  There  is  a 
strong  association  between  EBV-positivity  and 
histologic subtype: cases of MCHL are EBV + in 
about  75  %,  whereas  the  cases  of  NSHL  are 
positive in less than 20%. 
EBV genome products was shown to be clonal 
in  the  neoplastic  Hodgkin-Reed-Sternberg  (HRS) 
cells
25.  Its  presence  is  not  associated  with 
immunophenotypic characteristics of the HRS cells.
Epidemiological  Aspects  of  EBV+  HL:  The 
complex  epidemiology  of  HL  suggests  a 
multifactorial  aetiology.  Interactions  between 
genetic and environmental factors are probable. The 
contribution  of  EBV  to  HL  aetiology  differs 
according to age group and geographic origin
92-94. 
The  individual’s  age  at  the  time  of  primary 
EBV-infection  in  combination  with  his  genetic 
background appears to be important factors for the 
clinical  manifestations  of  the  infection.  When 
primary  infection  with  the  virus  occurs  in  early 
childhood, as is typical of developing countries, it is 
accompanied by, few if, any symptoms. If primary 
infection in contrast is delayed to adolescence, as 
often  is  seen  in  industrialized  countries,  it  is 
associated  with  the  clinical  syndrome,  infectious 
mononucleosis.
A wealth of cohort and case–control studies has 
shown  that  mononucleosis  is  followed  by  an 
increased risk of HL
95. In the largest study to date, a 
Scandinavian cohort study of 38000 mononucleosis 
patients, mononucleosis was associated with a more 
than 2.5-fold increased HL risk, which although it 
decreased with time remained significantly elevated 
for  up  to  two  decades
96.  Moreover,  because 
mononucleosis typically occurs in adolescence, HL 
risk  was  particularly  high,  3.5-fold  increased,  in 
young  adults.  Paradoxically,  EBV  is  particularly 
infrequently encountered in HL in young adults, the 
age  group  for  which  the  IM  association  is  the 
strongest. It appears, that earlier exposure to EBV 
protects  against  development  of  adolescent 
mononucleosis,  and  as  a  consequence  protects 
against young-adult onset EBV+ HL.  Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
At  variance  from  the  typical  bimodal  age 
distribution of HL in most developed nations, with 
an initial peak occurring among young adults aged 
15 to 39 years, in developing nations, the first peak 
occurs earlier, among children under age 15 years. 
(Figure  2).  HL  among  children  in  developing 
countries  are  characterized  by  a  particularly  high 
proportion of EBV+ cases. 
With respect to geographic variation, EBV rates 
in HL tumors from North America and Europe have 
been  reported  to  vary  between  20-50%,    while 
several  studies  from  Central  and  South  America 
showed  an  incidence  rates  varying  from  50  to 
95%
97-99. In a report from China, evidence of EBV 
expression in cases of HL reached 65%
100, and in a 
large series from Kenya, EBV was detected in 92% 
of HL cases
101. 
A  study  on  277  biopsies  from  10  countries 
revealed  a  particular  high  frequency  of  EBV-
positivity (80-100%) in childhood HL from Kenya, 
Costa Rica, Iran, but also from Greece, while EBV 
was  present  in  about  50%  of  pediatric  HL  cases 
from Egypt, Jordan,  South Africa  and the  United 
Kingdom
102.  A  case  series of childhood HL form 
Southeast Turkey showed the typical prevalence of 
male sex, mixed cellularity and EBV positivity
103.  
The  pattern  of  HL  in  Israel  is  intermediate 
between the bimodal pattern of Western countries 
and the pediatric peak seen in developing countries. 
Patients born in Europe had a slightly lower rate of 
positivity to EBV (21.8%). This rate was higher in 
patients from Asia and Africa (27%). In contrast to 
these  groups  of  Jews,  the  Bedouin  patients, 
although  representing  a  small  group,  showed a 
66.7% rate  of  EBV infection
104.  Studies form the 
middle East indicate incidence rates of EBV in HL 
varying  form  38-56  %  with  patterns  of  early-
industrialized  countries
105,106.  These  epidemiologic 
studies led to the proposal of a model by Jarrett et al 
that EBV-associated HL cases can be divided into 
three groups according to age at exposure to EBV 
and age at HL diagnosis
93. This model recognises a 
childhood group, accounting for almost all cases of 
HL in early childhood, a young adult group, which 
epidemiological  data  suggest  is  associated  with 
delayed exposure to EBV, and an older adult group, 
which might result from loss of the normal balance 
between latent EBV infection and host immunity.
Three epidemiological patterns can be discerned. 
The type I pattern which is prevalent in developing 
countries, shows a relatively high incidence in male 
children, a low incidence in the third decade and a 
second peak of high incidence in older age groups. 
Type  III,  which  is  usually  seen  in  developed 
countries, is characterised by a low rate in children 
and a pronounced initial peak in young adults. The 
third pattern (Type II), which is described in many 
Asian  countries,  is  intermediate  and  reflects  a 
transition  between  types  I and  III.  In this  pattern 
there is both a childhood and a third decade peak. 
An  interesting  question  is  whether  the 
socioeconomic progress will change the incidence 
patterns  of  HL  in  developing  countries.  Hjalgrim
and  colleagues  analysed HL incidence patterns in 
Singapore  between  1968  and  2004,  during  which 
time  period  a  socioeconomic  transition  towards 
Western  World  lifestyles  took  place
107.  A  HL 
incidence  peak  emerged  among  adolescents  and 
young  adults  in  Singapore  with  annual  increase 
rates  up  to  13.7%,  in  particular  in  females. 
However, the incidence peak remained considerably 
lower than what can be observed in young adults in 
the Western World. It remains to be determined to 
what extent the current lower incidence of HL in 
young  Asian  adults  should  be  attributed  to  birth 
cohort  phenomena,  as  would  be  suggested  by 
continued  increase  in  incidence,  and  to  ethnic 
variation  in  HL  susceptibility  between  Asian  and 
non-Asian populations, respectively.
The impact of socioeconomic and racial factors 
on the risk to  develop EBV+ HL was studied by 
Glaser et al in a Californian population
108. Tumor 
EBV-positivity  was  associated  with  Hispanic  and 
Asian/Pacific  Islander  (API)  but  not  black 
race/ethnicity,  irrespective  of  demographic  and 
clinical  factors.  In  Hispanics,  EBV+ HL  was 
associated not only with young and older age, male 
sex, and mixed cellularity histology, but also with 
foreign  birth  and  lower  neighbourhood 
socioeconomic status in females. The racial/ethnic 
variation suggests that EBV+ HL results from an 
intricate  interplay  of  early- and  later-life 
environmental,  hormonal,  and  genetic  factors 
leading to depressed immune function and poorly 
controlled EBV infection.
Genetic  predisposition  to  develop  EBV+  HL: 
Genetic  predisposition  to  develop  EBV+  HL  is 
supported by the association of EBV+ HL with the 
highly  polymorphic  human  leukocyte  antigen 
(HLA)  genes,  which  vary  by  racial/ethnic  group. 
Genetic association of EBV+ HL was found with 
the  HLA  class  I  region,  including  the  HLA-A 
gene
109,110.  HLA-A*02  was  underrepresented  in 
patients with EBV+ HL (15%), and HLA-A*01 was 
overrepresented in patients with EBV+ HL (37.1%). 
These  data  may  suggest  functional  differences  in 
the HLA-A alleles in the context of presentation of Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
EBV-derived  peptides.  HLA-A*02  can  present 
various immunogenic EBV-derived peptides of the 
latency type II antigens, and can mediate a cellular 
immune response, and thereby mediate a protective 
effect.
The distinct manifestations of EBV-infection are 
thought  to  be  affected  by  the  host’s  different 
immune response  to  EBV, especially by cytokine 
production. The levels of interleukin (IL)-1a, IL-2, 
IL-6, and interferon (IFN)- have been reported to 
be elevated in the serum of patients with infectious 
mononucleosis.  There  is  also  increasing  evidence 
indicating that cytokine gene polymorphisms, such 
as  those  of  the  IL-10  and  IL-1a  genes,  have  an
impact  on  susceptibility  to  EBV  infection.  We 
studied  several  polymorphic  allele  variants  of the 
cytokine  genes  IL-10  (T-3575A,  G-2849A,  C-
2763A, A-1082G and C-592A) in  HL patients
111. A 
subgroup of 71 samples were studied for the EBV 
status. EBV was detected in HRS cells in 20 of 71 
(28%) cases tested. No associations between EBV 
and cytokine polymorphisms were detected. 
In  Japanese  individuals,  the  polymorphism  of 
TGF-1  at  codon  10  was  associated  with  the 
development of EBV-related hematologic diseases, 
such  as  infectious  mononucleosis,  however 
associations  with  the  development  of  EBV+  HL 
have  not  been  reported  so  far
112.  Chang  et  al 
investigated  whether  polymorphic  variation  in 
genes involved in NF-kB activation and inhibition, 
other inflammatory pathways influenced HL risk
113. 
HL  risk  was  significantly  associated  with 
rs1585215  in  NF-kB1    and  with  NF-kB1 
haplotypes, with similar associations regardless of 
the tumor EBV status.
EBV and prognosis: The impact of the tumor cell 
EBV status on the prognosis of patients with HL 
remains  controversial.  Some  of  the  inter-study 
variation  may  be  attributable  to  the  different 
epidemiological features of the disease in different 
geographical settings and some may be related to 
case selection.
Considering  the  age-stratified  model  discussed 
above  seems to  be  important  when  analyzing  the 
impact  of  EBV  status  on  the  outcome  for  HL 
patients. Thus, in young adults, there seems to be a 
marginal prognostic advantage when patients carry
the EBV genome in their tumor
114-117. Yet among 
patients aged more than 50 years, EBV positivity 
was  associated  with  a  significantly  poorer 
outcome
115,118-120. In children aged < 15 years, some 
studies suggested that EBV presence was associated 
with favorable survival
120 while others suggested a 
negative impact  of EBV-positivity  on  outcome
121. 
Thus, the influence of EBV on survival in HL might 
reflect differences at the oncogenic capacity of the 
virus or in the immune response. The presence EBV 
might reflect a poor immune status, which in turn 
means that  patients might  tolerate  disease and its 
treatment less well. 
Circulating EBV-DNA as Biomarker: Detection 
and  quantitation  of  free  plasma  EBV  viral  DNA 
could potentially be used as a biomarker of disease 
activity  in  EBV+  HL.  A  number  of  groups  have 
explored the value of cell-free EBV-DNA viral load 
quantification  in  EBV-associated  malignancies 
including HL
122-125. The frequency of EBV-infected 
circulating  memory  B  cells  is  increased  in 
pretreatment  samples  of  EBV+ HL  patients 
compared with EBV- HL cases
126.
EBV genomes are detectable in the serum and 
plasma of EBV-associated HL cases. The origin of 
EBV genomes in serum/plasma varies in different 
disease states, in HL viral genomes are present as 
naked  DNA  and  are  probably  shed  from  tumors. 
Consistent with the notion that cell-free viral DNA 
may be shed from circulating apoptotic malignant 
cells,  it  has  been  shown  that  cell-free  DNA  is 
present as ‘‘naked’’ DNA rather than as virions
123. 
Using conventional PCR, Gallagher et al. reported 
that  EBV-DNA  was  detected  in  91%  of  serum 
samples  from  patients  with  EBV+ HL,  whereas 
23%  of  EBV- HL  patients  had  detectable  viral 
DNA. Using real-time PCR for EBV+ HL results 
were similar, and only 10% of patients with EBV-
HL had a quantifiable (low level) load, consistent 
with  lysis  of  bystander  EBV+  B  cells  within  the 
diseased  lymph  node.  Using  quantitative  (but  not 
real-time)  PCR,  Drouet  and  colleagues  confirmed 
the  observation  that  EBV-DNA  was  more 
frequently detected in serum from EBV+ HL than 
EBV- HL
127. Wagner et al. detected plasma EBV-
DNA by real-time PCR prior to therapy in 13 of 24 
pediatric patients with EBV seropositive HL, and in 
none of the patients in stable remission, suggesting 
that viral load monitoring may be useful in disease 
evaluation
128. However, this study did not test tissue 
samples for the presence of EBV within Hodgkin 
Reed-Sternberg cells and therefore was not able to 
stratify  between  EBV+  HL  and  EBV- HL  cases. 
Gandhi  detected EBV-DNA in  the plasma of all 
EBV+ patients with HL prior to therapy, while it 
was detected in peripheral blood monocytes only in 
50%  of EBV+ HL patients
124.  Plasma EBV-DNA 
was not detected in all patients with EBV- HL, and 
those with long-term remission. Serial analysis done Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
in  EBV+  HL  patients  who  presented  with  active 
disease showed that response to chemotherapy was 
associated with decline in viral load to undetectable 
levels.
The  variation  in  sensitivity  and  specificity  of 
EBV-DNA  as  a  biomarker  between  these  studies 
and  ours  may  in  part  be  reflected  by  technical 
differences in the assays employed. In this regard, 
the  use  of  new  generation  reagents  are  likely  to 
improve results.  The  sensitivity  of  real-time  PCR 
varies  with  the  efficiency  and  purity  of  DNA 
extraction,  the  segment  of  DNA  amplified,  the 
fluorogenic probe used, and potentially, the source 
of  DNA  (serum  versus  plasma).  Gandhi  et  al 
amplified  a  region  of  BALF5,  a  subunit  of  the 
EBV-DNA  polymerase  gene,  from  plasma 
samples
124. By contrast, the study by Wagner used 
primers to detect the BamH1-W region in plasma. 
This region is repeated a variable number of times, 
and  therefore, their  results  cannot  not  be  used to 
directly compare viral copy number
128. 
EBV  genome  copy  number  in  serum/plasma 
may provide an indication of tumor burden and may 
prove  to  be  a  useful  marker  for  monitoring  HL 
patients. Additional prospective studies are required 
to  further  evaluate  the  use  of  free  plasma  EBV-
DNA  as  a  biomarker  for  monitoring  response  to 
treatment in patients with EBV+ HL.
EBV  as  target  for  therapeutic  intervention  in 
HL: As the immunotherapeutic approach to EBV+ 
lymphoproliferative  diseases  including  HL  is  the 
topic of another review in this journal, we will limit 
this  subject  to  some  few  considerations.  The 
presence  of  EBV  latent  antigens  in  EBV+  HL 
appear  to  be  an  excellent  opportunity  both  for 
targeted  cellular  immunotherapy  and  antiviral 
strategies.  These  antigens  could  act  as  tumor-
associated  antigens  for  EBV-specific  cytotoxic  T 
cells  (CTL).  Antigen  processing  and  presentation 
appear to remain intact in EBV+ HL, however an 
impaired CTL response is observed in cases of HL. 
The  study  by  Gandhi  et  al.  suggests  that  Gal-1
hi
expression  in  HRS  cells  is  an  important  negative 
regulator  of  HL  tumour-associated  EBV  antigen-
specific  CD8+ T-cell immunity in  cHL,  and  thus 
enables  HRS  cells  to  avoid  T  cell  dependent 
immune  attack
129.  Galectin-1  (Gal-1)  is  a  soluble 
lectin  which  inhibits  proliferation  and  IFN-γ 
expression  by  EBV-specific  T-cells.  Targeted 
inhibition  of  Gal-1  expression  in  tumor  cells  has 
been  shown  to  potentiate  anti-tumor  effector  T 
cells.  The  Gal-1  mediated  immunosuppressive 
pathway may represent a target to enhance efficacy 
of immunotherapeutic strategies for HL.
Like  other  herpesviruses,  EBV  encodes  a 
thymidine  kinase  (TK)  enzyme  which  can  be  a 
target  for  purine  nucleoside  analogs,  such  as 
acyclovir (ACV) and ganciclovir (GCV). Latently 
infected B cells however do not express the EBV-
TK transcript or protein, and are unaffected by these 
antiviral agents. However, exposure of these cells in
vitro to arginine butyrate (or the sodium salt) results 
in modest induction of some lytic-phase genes and 
gene products, including TK
130.  Butyrate has been 
shown to sensitize EBV+ lymphoma cells in vitro to 
apoptosis  induced  by  ganciclovir.  Perrine  et  al 
administered arginine butyrate in combination with 
ganciclovir  in  15  patients  with  refractory  EBV+ 
lymphoid malignancies including one patient with 
EBV+  HL  to  evaluate  the  drug  combination  for 
toxicity,  pharmacokinetics,  and  clinical 
responses
131.  Ganciclovir  was  administered  twice 
daily at standard doses, and arginine butyrate was 
administered  by  continuous  infusion  in  an 
intrapatient  dose  escalation,  from  500  mg/kg/day 
escalating to 2000 mg/kg/day, as tolerated, for a 21-
day  cycle.  The  MTD for  arginine  butyrate  in 
combination  with  ganciclovir  was  established  as 
1000  mg/kg/day.  Ten  of  15  patients  showed 
significant antitumor responses, with 4 CRs and 6 
PRs within one treatment cycle. The single patient 
with HL demonstrated no response to the protocol. 
Review of pathology before therapy was instituted 
showed that only a single lymph node was positive 
for  EBV  antigens,  whereas  the  patient’s  large 
central mediastinal masses were negative for EBV.
In conclusion, studies on the role of EBV in the 
immunopathogenesis  of  HL  have  delivered 
important  insights  which  form  the  basis  for 
therapeutic  approaches  targeting  EBV.  Recent 
progress    may  help  to  overcome  obstacles 
encountered  on  the  way  to  a  targeted  therapy  in 
EBV+ HL.
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